AP Biosciences Inc (6945)の価格はいくらですか

AP Biosciences Inc (6945)の価格は$3.06です

AP Biosciences Inc (6945)の時価総額は何ですか

AP Biosciences Inc (6945)の時価総額は$296.40Mです

AP Biosciences Inc（6945）の株価履歴

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.

年	パフォーマンス
2026 (TTM)	-13.12%
2025	237.19%
2024	4.26%
2023	0.00%

年

パフォーマンス

2026 (TTM)

-13.12%

2025

237.19%

2024

4.26%

2023

0.00%

企業	株価	変化率 1年%	国
Vertex Pharmaceuticals Incorporated VRTX.US	$548.15	36.70%	US
Argenx SE ARGX.US	$1.03K	45.33%	NL
Moderna, Inc. MRNA.US	$153.87	536.09%	US
CSL Limited CSL.AX	$121.53	-10.53%	AU
Lonza Group AG LONN.SW	$748.60	6.90%	CH

企業

株価

変化率 1年%

国